GLP-1 receptor agonists and immune checkpoint inhibitor therapy: a narrative review on mechanistic and clinical evidence [0.03%]
GLP-1受体激动剂与免疫检查点抑制剂治疗：机制和临床证据的叙述性回顾
Connor Frey
Connor Frey
Obesity paradoxically increases sensitivity to immune checkpoint inhibitors (ICIs) despite elevating cancer risk, creating a clinical opportunity where metabolic dysfunction may generate a target-rich immune microenvironment. However, immun...
Primary prophylaxis with pegylated G-CSF is associated with improved treatment completion and progression-free survival in locally advanced cervical cancer undergoing concurrent chemoradiotherapy: a retrospective cohort study [0.03%]
聚乙二醇G-CSF一线预防与局部晚期宫颈癌同步放化疗的完成率提高及无进展生存期延长相关性研究：一项回顾性队列研究
Qiang Du,Qing Liu,Yingnan Zhou et al.
Qiang Du et al.
Background: Concurrent cisplatin-based chemoradiotherapy (CCRT) for locally advanced cervical cancer is often limited by severe neutropenia. This study evaluated whether primary prophylaxis with pegylated recombinant huma...
How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 study [0.03%]
关于enfortumab vedotin联合派姆单抗与基于铂的化疗对晚期尿路上皮癌患者生活质量的影响：EV-302研究中患者报告结果的简易解读
Shilpa Gupta,Yohann Loriot,Michiel S Van der Heijden et al.
Shilpa Gupta et al.
Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma [0.03%]
LOGIC 2研究的通俗版本：对BRAF V600突变型黑色素瘤患者采用encorafenib、binimetinib以及第三种药物进行治疗
Reinhard Dummer,Shahneen Sandhu,Wilson H Miller Jr et al.
Reinhard Dummer et al.
A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer [0.03%]
BRAF V600E突变型转移性非小细胞肺癌患者使用encorafenib联合binimetinib的PHAROS研究更新结果的通俗解读
Melissa L Johnson,Egbert F Smit,Enriqueta Felip et al.
Melissa L Johnson et al.
A study to learn how well the combination of encorafenib and binimetinib works and how safe it is in adults with thyroid cancer: a plain language summary [0.03%]
关于恩考芬尼与比美替尼联合治疗成人甲状腺癌疗效及安全性的研究：简易概述
Makoto Tahara,Naomi Kiyota,Hiroo Imai et al.
Makoto Tahara et al.
Real-world sequential treatment patterns and outcomes in the new era of immunotherapy for advanced gastric cancer in Japan [0.03%]
免疫检查点抑制剂应用于晚期胃癌的现实世界中的序贯治疗模式及疗效
Hisato Kawakami,Yoshinori Tanizawa,Tetsu Shimizu
Hisato Kawakami
Background: We investigated treatment patterns and outcomes in patients with advanced gastric cancer (AGC) after nivolumab first-line therapy approval in Japan in 2021. ...
Predictors of long-term anamorelin hydrochloride use in patients with cancer cachexia: a single-center real-world retrospective study [0.03%]
癌症恶病质患者长期使用盐酸安莫西林的预测因素：单中心真实世界回顾性研究
Yuko Kanbayashi,Takeshi Ishikawa,Hayato Kawachi et al.
Yuko Kanbayashi et al.
Aim: This retrospective study aimed to identify clinical factors associated with the long-term continuation of anamorelin hydrochloride in real-world clinical practice. ...
AGMT mCRC Registry Third-Line and Beyond: a multicentric real-world platform with integrated imaging and biosample database for later-line metastatic colorectal cancer [0.03%]
AGMT mCRC登记处第三线及以后：一个具有集成影像和生物样本数据库的多中心真实世界平台，用于晚期转移性结直肠癌患者
Florian Huemer,Gudrun Piringer,Wolfgang Eisterer et al.
Florian Huemer et al.
Background: The treatment landscape of systemic third- and later-line therapy in metastatic colorectal cancer (mCRC) continues to evolve. We, therefore, established the Austrian Group of Medical Tumor Therapy (AGMT) mCRC ...
The safety and efficacy of recombinant human adenovirus 5 injection (H101) intraperitoneal administration combined with tislelizumab and platinum, fluorouracil-based drugs in the treatment of gastric cancer with peritoneal metastasis: an open-label, single-arm, prospective clinical study protocol [0.03%]
重组人腺病毒5注射液（欣普瑞）联合替雷利珠单抗及铂类、氟尿嘧啶类药物治疗胃癌腹膜转移的开放性单臂前瞻性临床研究方案：安全性与有效性
Jiasheng Zong,Zhongyi Dong,Yujing Guan et al.
Jiasheng Zong et al.
This prospective, open-label, single-arm, exploratory clinical trial aims to evaluate the safety and efficacy of intraperitoneal perfusion of recombinant human adenovirus type 5 (H101) in combination with systemic tislelizumab and platinum-...